Afinitor for Neuroendocrine tumors of Gastrointestinal or Lung origin – Details


( Last Updated : December 16, 2016)
Generic Name:
Everolimus
Project Status:
Complete
Therapeutic Area:
Neuroendocrine tumors (NET) of Gastrointestinal or Lung origin
Manufacturer:
Novartis Pharmaceuticals Canada Inc.
Brand Name:
Afinitor
Project Line:
Reimbursement Review
Project Number:
PC0083-000
NOC Status at Filing:
Post NOC
NOC Date:

Details


Strength:
2.5 mg, 5mg, 7.5mg and 10 mg tablets
Tumour Type:
Endocrine
Indications:
Neuroendocrine tumours of Gastrointestinal or Lung origin
Funding Request:
For the treatment of unresectable, locally advanced or metastatic, well differentiated non-functional neuroendocrine tumours (NET) of gastrointestinal or lung origin in adults with progressive disease
Sponsor:
Novartis Pharmaceuticals Canada Inc.
Submission Date:
Submission Deemed Complete:
Prioritization Requested:
Not Requested
Stakeholder Input Deadline ‡:
Check-point meeting:
pERC Meeting:
Initial Recommendation Issued:
Feedback Deadline ‡:
Notification to Implement Issued:
Recommendation Type:
Reimburse with clinical criteria and/or conditions
pERC Meeting:
Final Recommendation Issued:

Files

‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.